Table 1.

Characteristics of the 9 randomized controlled trials included in the analysis

Study	Study design	Population	Duration	Resveratrol group	Control group	Outcomes
Brasnyo et al.	Randomized placebo-controlled double-blinded parallel clinical trial	N = 19 patients with T2DM	4 weeks	N = 10;10 mg/d	N = 9; Placebo	Fasting plasma glucose, fasting insulin, HbA1c, HOMA-IR
Bhatt et al.	Open-label, randomized, controlled trial	N = 57 patients with T2DM	3 months	N = 28;250 mg/d	N = 29; Empty-control	Fasting plasma glucose, HbA1c
Movahed et al.	Randomized placebo-controlled double-blinded parallel clinical trial	N = 64 patients with T2DM	45 days	N = 33;1 g/d	N = 31; Placebo	Fasting plasma glucose, fasting insulin, HbA1c, HOMA-IR
Goh et al.	Randomized double-blind	N = 10 patients with T2DM	12 weeks	N = 5;3 g/d	N = 5; Placebo	Fasting plasma glucose, fasting insulin, HbA1c, HOMA-IR
Tome-Carneiro et al.	Randomized placebo-controlled triple -blinded parallel clinical trial	N = 35 patients with T2DM	12 months	N = 13; RSV-enriched grape extract (8 mg/d)	N = 22; Placebo	Fasting plasma glucose, HbA1c
Bashmakov et al.	Randomized placebo-controlled examiner -blinded parallel clinical trial	N = 24 patients with diabetic foot syndrome	60 days	N = 14; 50 mg/day	N = 10; Placebo	Fasting plasma glucose, fasting insulin
Thazhath et al.	Randomized, double-blind, crossover design	N = 14 patients with T2DM	5 weeks	N = 14;1 g/d	N = 14; Placebo	Fasting plasma glucose, HbA1c
Timmers et al.	Randomized double-blind crossover study	N = 17 patients with T2DM	30 days	N = 17;150 mg/d	N = 17; Placebo	Fasting plasma glucose, fasting insulin, HbA1c, HOMA-IR
Javid et al.	Randomized placebo-controlled double-blinded parallel clinical trial	N = 43 patients with T2DM	4 weeks	N = 21;480 mg/d	N = 22; Placebo	Fasting plasma glucose, fasting insulin, HOMA-IR

T2DM type 2 diabetes mellitus, HOMA-IR homeostasis model assessment of insulin resistance, HbA1C glycated hemoglobin A